New combo aims to extend life in stomach cancer
NCT ID NCT03081143
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a combination of ramucirumab plus FOLFIRI (a standard chemo regimen) works better than ramucirumab plus paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has worsened after one prior chemo treatment. About 429 participants will be randomly assigned to one of the two combos. The goal is to see which combo helps people live longer and shrinks tumors more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ramucirumab plus FOLFIRI (irinotecan, leucovorin, 5-FU) or ramucirumab plus paclitaxel
What this could lead to
If successful, this could offer a new standard second-line treatment option for advanced gastric cancer, potentially improving survival.
What could go wrong
This is a mid-to-late-stage trial, but the experimental combo may not prove better than the current standard. Side effects from chemotherapy and ramucirumab (e.g., bleeding, fatigue) are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC OR EGJ CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
-
HELIOS Klinikum Bad Saarow
Bad Saarow, Germany
-
HELIOS Klinikum Berlin Buch
Berlin, Germany
-
Hämatologisch-Onkologische Praxis Eppendorf (HOPE)
Hamburg, Germany
-
Kliniken Essen Mitte
Essen, Germany
-
Klinikum Bielefeld Mitte
Bielefeld, Germany
-
Krankenhaus Nordwest
Frankfurt, Germany
-
Landeskrankenhaus Feldkirch - Rankweil
Rankweil, Vorarlberg, 6830, Austria
-
Ordensklinikum Linz GmbH, Barmherzige Schwestern
Linz, Upper Austria, 4010, Austria
-
Ortenau Klinikum
Lahr, Germany
-
Technische Universität München
München, 81675, Germany
-
U.O. Oncologia Medica, Università Cattolica Sacro Cuore
Rome, Italy
-
Universitäres Krebszentrum Leipzig
Leipzig, Germany
-
Universitätsklinikum Tübingen
Tübingen, Germany
-
Universitätsklinikum Ulm
Ulm, Germany
-
Wiener Neustadt, Landesklinikum
Wiener Neustadt, 2700, Austria